STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #284 by analyst upside · 2026-09-08
LXEO
Lexeo Therapeutics, Inc.
Healthcare · Market Cap $401M · P/E 0x
ANALYST PRICE TARGET
+315.1%
implied upside to consensus target
Current Price $4.89
Consensus Target $20.3
Bull Target $30.0
Bear Target $9.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
8
Hold
0
Sell
0
52-Week Low $3.99
52-Week High $10.99
YTD Return -49.1%
FUNDAMENTALS
Market Cap $401M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.88
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.99
52-Week High $10.99
Current Price $4.89
Bear Target $9.0
Bull Target $30.0
● Now $4.89 ● Target $20.3
TRADING DATA
Avg Volume 929K
YTD Return -49.1%
Analyst Count 10
Consensus Buy
Upside to Target +315.1%
Last Updated 2026-09-08

ANALYST SUMMARY

Lexeo Therapeutics, Inc. (LXEO) is currently trading at $4.89 with a Wall Street consensus price target of $20.3, implying potential upside of 315.1% over the next 12 months. 10 analysts currently cover LXEO, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $9.0.

LXEO operates in the Healthcare sector with a market capitalisation of $401M. The stock is down 49.1% year-to-date and is currently trading near the lower end of its 52-week range of $3.99 – $10.99.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LXEO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan - Reiterated
Overweight → Overweight 2026-06-25 43% win rate (7 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-05-11 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-01-13 33% win rate (6 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-01-13 31% win rate (48 calls)
Raymond James ● Initiated
Strong Buy 2025-12-18 Building track record
Chardan Capital - Reiterated
Buy → Buy 2025-12-11 33% win rate (6 calls)
Cantor Fitzgerald ● Initiated
Overweight 2025-12-01 40% win rate (10 calls)
Cantor Fitzgerald ● Initiated
Overweight 2025-11-20 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
45
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →